Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice

Biochemical Pharmacology

Volumn 53, Issue 8, 1997, Pages 1197-1202

  Raghunathan, Kamasamudram ^a   Schmitz, John C ^a   Priest, David G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

dietary folate depletion; fluorouracil; leucovorin; mammary adenocarcinoma; mouse model

Indexed keywords

DRUG METABOLITE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; METHYLENETETRAHYDROFOLIC ACID; TETRAHYDROFOLIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; FOLIC ACID DEFICIENCY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIET; DRUG SYNERGISM; FLUOROURACIL; FOLIC ACID DEFICIENCY; LEUCOVORIN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE;

EID: 0030943953     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00829-5     Document Type: Article

References (27)

1. Mini E, Trave F, Rustum YM and Bertino JR, Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 47: 1-19, 1990.
2. Buroker TR, O'Connell MJ, Wieand S, Krook JE, Gersfner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG and Gesme DH Jr, Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20, 1994.
3. Trave F, Rustum YM, Petrelli NJ, Herrera L, Mittelman A, Frank C and Creacen PJ, Plasma and tumor tissue pharmacology of intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol 6: 1184-1191, 1988.
4. Danenberg PV and Danenberg KD, Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthase: Evidence for an ordered mechanism. Biochemistry 17: 4018-4024, 1978.
5. Moran RG and Keyomarsi K, Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263: 14402-14409, 1988.
6. Pinedo HM and Peters GJ, 5-Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
7. Tominaga T, Toi M and Shirasaka T, Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S]leucovorin combination therapy for breast cancer. Anticancer Res 13: 2425-2428, 1993.
8. Dohden K, Ohmura K and Watanabe Y, Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. Cancer 71: 471-480, 1993.
9. Wright JE, Dryefuss A, El-Magharbel I, Trites D, Jones SM, Holden SA, Rosowsky A and Frei E III, Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 49: 2592-2596, 1989.
10. Nadal JC, Van Groeningen CJ, Pinedo HM and Peters GJ, In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 42: 387-393, 1988.
11. Carlsson G, Gustavsson B, Frosing R, Odin E, Hafstrom LO, Spears CP and Larsson PA, Antitumor effects of pure diastereoisomers of 5-formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model. Biochem Pharmacol 50: 1347-1351, 1995.
12. Houghton JA, Williams LG, Loftin SK, Cheshire PJ, Morton CL, Houghton PJ, Dayan A and Jolivet J, Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 30: 423-432, 1992.
13. Schmitz JC, Grindey GB, Schultz RM and Priest DG, Impact of dietary folic acid on reduced folates in mouse plasma and tissues: Relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 48: 319-325, 1994.
14. Henderson GB, Folate-binding proteins. Annu Rev Nutr 10: 319-335, 1990.
15. Pinter K, Davisson VJ and Santi DV, Cloning, sequencing, and expression of the Lactobacillus casei thymidylate synthase gene. DNA 7: 235-241, 1988.
16. Mathews RG, Methylenetetrahydrofolate reductase from pig liver. Methods Enzymol 122: 372-381, 1986.
17. Rios-Orlandi EM, Zarkadas CG and MacKenzie RE, Formyltetrahydrofolate dehydrogenase-hydrolase from pig liver: Simultaneous assay of the activities. Biochim Biophys Acta 871: 24-35, 1986.
18. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
19. Priest DG, Schmitz JC, Bunni MA and Stuart RK, Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83: 1806-1812, 1991.
20. Priest DG and Doig MT, Tissue folate polyglutamate chain length determination by electrophoresis as thymidylate synthase-fluorodeoxyuridylate ternary complexes. Methods Enzymol 122: 313-319, 1986.
21. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A and Macdonald JS, Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13: 1303-1311, 1995.
22. Levin RD and Gordon JH, Fluorodeoxyuridine with continuous leucovorin infusion. A Phase II clinical trial with metastatic colorectal cancer. Cancer 72: 2895-2901, 1993.
23. Morgan RJ Jr, Speyer J, Doroshow JH, Margolin K, Raschko J, Sorich J, Akman S, Leong L, Somlo G, Vaslilev S, Ahn C, Johnson D and Beller U, Modulation of 5-fluorouracil with high-dose leucovorin calcium: Activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol 58: 70-85, 1995.
24. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Prac Natl Acad Sci USA 87: 492-496, 1990.
25. Radpavar S, Houghton PJ and Houghton JA, Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38: 335-342, 1989.
26. Priest DG, Veronee CD, Mangum M, Bednarek JM and Doig MT, Comparison of folylpolyglutamate hydrolases of mouse liver, kidney muscle and brain. Mol Cell Biochem 43: 81-87, 1982.
27. Wang Y, Nimec Z, Ryan TJ, Dias JA and Galivan J, The properties of the secreted γ-glutamyl hydrolases from H35 hepatoma cells. Biochim Biophys Acta 1164: 227-235, 1993.